SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

29 Jul 2025 Evaluate
A slight decline in the revenue of Rs. 4986.16 millions was seen for the June 2025 quarter as against Rs. 5130.00 millions during year-ago period.The Company has registered profit of Rs. 133.47  millions for the quarter ended June 2025, a growth of 23.20%  over Rs. 108.34 millions millions achieved in the corresponding quarter of last year.The company reported a degrowth in operating Profit to 689.89 millions from 731.39 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 4986.16 5130.00 -2.80 4986.16 5130.00 -2.80 21394.23 18661.17 14.65
Other Income 17.58 80.91 -78.27 17.58 80.91 -78.27 461.88 587.11 -21.33
PBIDT 689.89 731.39 -5.67 689.89 731.39 -5.67 3086.30 2092.16 47.52
Interest 304.48 405.13 -24.84 304.48 405.13 -24.84 1459.12 1393.77 4.69
PBDT 385.41 326.26 18.13 385.41 326.26 18.13 1626.91 644.74 152.34
Depreciation 221.38 206.22 7.35 221.38 206.22 7.35 846.08 874.07 -3.20
PBT 164.03 120.04 36.65 164.03 120.04 36.65 780.83 -229.33 -440.48
TAX 30.56 11.70 161.20 30.56 11.70 161.20 189.27 13.42 1310.36
Deferred Tax 31.03 1.11 2695.50 31.03 1.11 2695.50 203.91 14.61 1295.69
PAT 133.47 108.34 23.20 133.47 108.34 23.20 591.56 -242.75 -343.69
Equity 921.63 919.17 0.27 921.63 919.17 0.27 921.63 919.00 0.29
PBIDTM(%) 13.84 14.26 -2.95 13.84 14.26 -2.95 14.43 11.21 28.67

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×